Combating infections in neutropenic patients

In febrile neutropenic patients, most of whom have cancer, immediate, albeit empiric, antibiotic therapy reduces infectious morbidity and mortality. With respect to definitive therapy, it is stressed that isolate patterns are changing, even as new antibiotics are becoming available. Issues such as single-agent versus combination therapy, as well as preventive strategies, are reviewed.